

Carmen Herranz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3767766/publications.pdf>

Version: 2024-02-01

15
papers

356
citations

1040056

9
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

817
citing authors

#	ARTICLE	IF	CITATIONS
1	AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3604-3613.	7.1	96
2	Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Bioscience Reports, 2014, 34, .	2.4	73
3	Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape. Cancer Research, 2018, 78, 6059-6072.	0.9	40
4	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	5.9	34
5	Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models. Npj Systems Biology and Applications, 2019, 5, 7.	3.0	30
6	Modification of BRCA1-associated breast cancer risk by HMMR overexpression. Nature Communications, 2022, 13, 1895.	12.8	19
7	Lymphangioliomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS ONE, 2015, 10, e0132546.	2.5	15
8	Tumor xenograft modeling identifies TCF4/ITF2 loss associated with breast cancer chemoresistance. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	15
9	Study of breast cancer incidence in patients of lymphangioliomyomatosis. Breast Cancer Research and Treatment, 2016, 156, 195-201.	2.5	9
10	Altered regulation of <i>BRCA1</i> exon 11 splicing is associated with breast cancer risk in carriers of <i>BRCA1</i> pathogenic variants. Human Mutation, 2021, 42, 1488-1502.	2.5	7
11	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	4.1	6
12	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioliomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	6.9	6
13	Heterogeneity and Cancer-Related Features in Lymphangioliomyomatosis Cells and Tissue. Molecular Cancer Research, 2021, 19, 1840-1853.	3.4	3
14	Risk of breast cancer in patients with lymphangioliomyomatosis. Cancer Epidemiology, 2019, 61, 154-156.	1.9	2
15	Evidence for shared genetic risk factors between lymphangioliomyomatosis and pulmonary function. ERJ Open Research, 2022, 8, 00375-2021.	2.6	0